Ozempic vs Wegovy: Key Differences Explained

Educational only, not medical advice; consult a licensed clinician.

Ozempic and Wegovy are both brand-name injectable medications that contain the same active ingredient, semaglutide, a GLP-1 receptor agonist. Although they share a molecule, they are approved by the FDA for different uses and are dosed differently. Below is a grounded overview to help patients in the Louisville and Kentucky area understand how they compare.

Same Drug, Different Approvals

The most important point is that Ozempic and Wegovy are both semaglutide, manufactured by Novo Nordisk. The difference lies in their FDA-approved indications and labeled dosing rather than the underlying compound.

• Ozempic is approved to improve blood sugar (glycemic) control in adults with type 2 diabetes, and to reduce the risk of major cardiovascular events in adults with type 2 diabetes and established cardiovascular disease.
• Wegovy is approved for chronic weight management in adults and certain adolescents who meet specific body mass index (BMI) criteria, used alongside a reduced-calorie diet and increased physical activity.

How They Work

As GLP-1 receptor agonists, both medications mimic a naturally occurring hormone that helps regulate appetite, slow gastric emptying, and support insulin release in response to food. This shared mechanism explains why both can influence appetite and weight, even though only Wegovy is labeled specifically for weight management.

Dosing Differences

Both are given as a once-weekly subcutaneous injection, but the maximum labeled doses differ. Dosing is titrated gradually to reduce gastrointestinal side effects. Wegovy is labeled to reach a higher maintenance dose than Ozempic. Specific dose levels and titration schedules are determined by a clinician based on the product label and individual response.

Side Effects

Because they share an active ingredient, Ozempic and Wegovy have overlapping side effect profiles. Commonly reported effects include nausea, vomiting, diarrhea, constipation, and abdominal discomfort, which often lessen over time as the dose is titrated. Both carry a boxed warning regarding the risk of thyroid C-cell tumors observed in rodent studies; they are not recommended for people with a personal or family history of medullary thyroid carcinoma or Multiple Endocrine Neoplasia syndrome type 2. Any concerning symptoms should be discussed with a clinician.

Frequently Asked Questions

Are Ozempic and Wegovy the same medication?

They contain the same active ingredient, semaglutide, and are made by the same manufacturer. They differ in their FDA-approved uses and labeled dosing. Ozempic is approved for type 2 diabetes and cardiovascular risk reduction, while Wegovy is approved for chronic weight management.

Can Ozempic be used for weight loss?

Ozempic is FDA-approved for type 2 diabetes, not for weight loss. While weight change can occur with GLP-1 receptor agonists, using a medication outside its labeled indication is a clinical decision that should be made with a licensed clinician.

Which one causes more side effects?

Because both contain semaglutide, their side effect profiles overlap. Gastrointestinal effects such as nausea are common with both and tend to improve as the dose is gradually increased. Individual tolerance varies.

How are they administered?

Both are once-weekly subcutaneous (under-the-skin) injections, typically self-administered with a prefilled pen after appropriate instruction from a clinician or pharmacist.

How do I know which option is appropriate for me?

The right choice depends on your medical history, current conditions, and treatment goals. A licensed clinician can review your health profile and discuss options. You can begin by completing our health assessment.

Educational only, not medical advice; consult a licensed clinician.